Trodelvy met the primary endpoint in the TROPiCS02 study in extensively pretreated HR+/HER2 breast cancer patients

1. ASCO CONFERENCE 2022 DELVEINSIGHT
Trodelvy met the primary endpoint in the TROPiCS02
study in extensively pretreated HR+/HER2 breast cancer
patients
In a Phase III trial, Gilead Sciences' Trodelvy met the primary endpoints, lowering the
probability of disease progression or death by 30%. In TROPiCS-02, Trodelvy was compared to
chemotherapy in third-line HER2+, ER+ breast cancer. The anti-Trop-2 antibody-drug conjugate
(ADC), which is already approved for third-line or later triple-negative breast cancer and post-
chemo/PD-(L) 1 urothelial bladder cancer, has taken a significant stride ahead.
The trial also continues to examine patients for overall survival, an important secondary
objective, and the data will be presented in the Oral Abstract Session at the ASCO 2022
conference on June 4, 2022. Given that Gilead did not provide an affirmative response to the
meaningful clinical trial, the conference outcomes will be intriguing to observe.
The DESTINY Breast04 study, led by AstraZeneca, is the first high-phase trial for HER2 low
metastatic breast cancer patients.
Check Out:- Breast Cancer Treatment

2. ASCO CONFERENCE 2022 DELVEINSIGHT
Abstract LBA3: The DESTINY Breast04 study, led by AstraZeneca, is the first high-
phase trial for HER2 low Metastatic Breast Cancer
DESTINY-Breast04 is the first Phase III trial of a HER2-directed therapy in patients with HER2-
low metastatic breast cancer to show a statistically significant and clinically meaningful
improvement in progression-free and overall survival when compared to standard therapy.
Trastuzumab deruxtecan is already approved in the United States and other countries as a
third-line treatment for metastatic HER2+ breast cancer. According to the business, both the
primary and secondary endpoints have been fulfilled, and the results will be presented as a
Plenary Session at the ASCO 2022 conference on June 5, 2022. In addition, the company is
sharing the safety follow-up data from the randomised Phase III DESTINY Breast03 trial in
collaboration with Daiichi Sankyo (Abstract: 1000).
Lasofoxifene, a powerful oral selective oestrogen receptor modulator (SERM), developed by
Sermonix Pharmaceuticals, could play a key role in the focused precision medicine therapy of
advanced ER+ breast cancer.
The bioavailability and activity of lasofoxifene in oestrogen receptor mutations may hold
promise for patients who have developed endocrine resistance as a result of ESR1 mutations,
which is a common finding in metastatic patients and a medical necessity. Sermonix's primary
candidate is now undergoing testing in Phase II. Apart from the already approved tamoxifen,
which has been used for decades, it is the only emerging SERM in the second- and third-line
context, along with Veru Pharma's Enobosarm. We eagerly await the results of the Phase II trial,
which will be presented as a Poster Discussion Session at the ASCO 2022 conference on June 6,
2022.
Abstract 528: The preoperative window of opportunity (WOO) research in postmenopausal
patients with ER+/HER2 primary breast cancer will be presented by Sanofi's highly anticipated
AMEERA-4.
Following the failure of AMEERA-3 and the cancellation of the AMEERA-4 trial, the company will
present its preoperative window for the AMEERA-4 trial as a poster session at the ASCO 2022
conference on June 6, 2022. Because of Sanofi's oral SERD's past failures, it will be interesting to
see how amcenestrant or letrozole fare in postmenopausal patients with ER+/HER2 primary
breast cancer.
Abstract TPS1118: Merck’s KEYNOTE-B49: A Phase III trial in patients with HR+/HER2- locally
recurrent inoperable or metastatic breast cancer.
Merck’s top product, Keytruda, combined with chemotherapy, may enhance patient outcomes
in HR+/HER2 given that patients with triple-negative breast cancer (TNBC), including those with
metastatic disease (KEYNOTE-355) and those with early-stage illness, have shown benefits with

3. ASCO CONFERENCE 2022 DELVEINSIGHT
Keytruda. However, none of the PD-1 inhibitors till now have been able to make their mark in
the breast cancer space. Moreover, this is a trial in progress currently, and we do not expect
any significant data readout at this moment.
Abstract TPS1121: Veru’s ENABLAR-2 trial: The first-in-class oral molecule targeting
AR+ER+HER2 Breast Cancer
Veru Pharma recently collaborated with Eli Lilly and Company to evaluate enobosarm in
combination with Verzenio in the Phase III ENABLAR-2 Trial. The ENABLAR-2 trial will assess the
efficacy and safety of the enobosarm and abemaciclib combination in patients who have
previously received first-line therapy of palbociclib and estrogen-blocking agent combination in
AR+ER+HER2− metastatic breast cancer.
Abstract TPS1130: CART development in metastatic breast cancer
Early clinical trials have shown that CAR T (chimeric antigen receptor T) is effective in the
treatment of haematological malignancies. CAR-Ts have had more success in haematological
malignancies than solid tumours, therefore it will be intriguing to follow their progress in breast
cancer. We anticipate the corporation presenting the findings as a Poster Session at the ASCO
2022 conference on June 6, 2022.
Abstract 1021: Eli Lilly’s Imlunestrant, an oral SERD for ESR1 mutation in ER-positive (ER+)
advanced breast cancer
The monotherapy data from the EMBER trial are set to be presented by Eli Lilly. Imlunestrant
(LY3484356) demonstrated promising effectiveness and pharmacokinetic (PK) features in ESR1
mutants, including anticancer activity. The medicine showed a positive safety profile, according
to the preliminary study data presented at ASCO 2021. We expect favourable results from the
monotherapy on June 6, 2022, during the ASCO 2022 conference's Poster Discussion Session.
Conclusion
Only DESTINY Breast04 and TROPICS2 drew our attention among the several studies presented
at ASCO 2022, since their successful conclusion could enable dramatic improvements in this
area. In addition, we anticipate that innovative medicines such as CAR T will be transformative
in the future years. After the trial is completed, it will be interesting to see Sanofi's presentation
for the AMEERA 4 trial. With lasofoxifene, the sole SERM in second- and third-line therapy,
Sermonix has to be one of the front runners this year. Apart from that, Ibrance's updated
efficacy data for PALOMA-2 and PALOMA-3 will be given.
To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed
Coverage | ASCO 2022 Conference | ASCO Conference 2022 | ASCO Abstract 2022

4. ASCO CONFERENCE 2022 DELVEINSIGHT
Some of the Latest ASCO Abstract 2022 Launched:
 Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-line setting
for the patients with R/R Large B-cell lymphoma (LBCL)?
 Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in
Multiple Myeloma during ASCO 2022.
 Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully Targets NRG1
Fusions in Lung and Pancreatic Cancer
Recent Pharmaceuticals Research Reports by Delveinsight
 Technical Due Diligence Firms
 Facial Lines Market
 Adult T-Cell Leukemia-Lymphoma Market
 Shingles Market
 Kaposi’s Sarcoma Market
 Surgical Mask & Respirator Market
 Plaque Modification Devices Market
 Stem Cell Market
 Inflammatory Pain Market
 Hepatic Cirrhosis Market
 Sly Syndrome Market
 Shigellosis Market
 Tuberculosis Market
 Asperger Syndrome Market
 B-Cell Maturation Antigen Targeted Therapies Market
 Oncolytic Virus Cancer Therapy Pipeline
 Sick Sinus Syndrome Market
 Urinary Catheters Market
 Medical Marijuana Market

5. ASCO CONFERENCE 2022 DELVEINSIGHT
 B Cell Chronic Lymphocytic Leukemia Market
Trending & Popular Research Reports by Delveinsight
 CAR-T Pipeline
 Biotech Consulting
 Wolman Disease Market
 Diabetic Wounds Market
 Smoking Cessation and Nicotine Addiction Market
 Neuroendocrine Tumors Market
 Angio Suites Market
 Liquid Biopsy for Cancer Diagnostics Market
 Pancreatic Endocrine Tumor Market
 Uveal Neoplasms Market
 Systemic Inflammatory Response Syndrome Market
 Familial Lipoprotein Lipase Deficiency Market
 ASMD Market
 PCSK9 Market
 Ventral Hernia Market
 Bacterial Pneumonia Market
 Diabetes Insipidus Market
 Hay Fever Conjunctivitis Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business
solutions for life science vertical and offering quintessential advisory services in the areas of
R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and
Mergers & Acquisitions.
Contact Us

6. ASCO CONFERENCE 2022 DELVEINSIGHT
Yash
info@delveinsight.com